Spero Therapeutics EBITDA vs. Market Capitalization
| SPRO Stock | USD 1.13 0.02 1.74% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 25.8 M | Current Value 27.1 M | Quarterly Volatility 32.8 M |
For Spero Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Spero Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Spero Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Spero Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Spero Therapeutics over time as well as its relative position and ranking within its peers.
Spero |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.08 | Revenue Per Share 2.223 | Quarterly Revenue Growth 2.754 | Return On Assets 0.1048 |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Spero Therapeutics Market Capitalization vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Spero Therapeutics's current stock value. Our valuation model uses many indicators to compare Spero Therapeutics value to that of its competitors to determine the firm's financial worth. Spero Therapeutics is currently regarded as top stock in ebitda category among its peers. It is rated fifth in market capitalization category among its peers creating about 2.39 of Market Capitalization per EBITDA. At this time, Spero Therapeutics' EBITDA is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Spero Therapeutics' earnings, one of the primary drivers of an investment's value.Spero Market Capitalization vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Spero Therapeutics |
| = | 25.77 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Spero Therapeutics |
| = | 61.61 M |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Spero Market Capitalization vs Competition
Spero Therapeutics is rated fifth in market capitalization category among its peers. Market capitalization of Health Care industry is at this time estimated at about 1.47 Billion. Spero Therapeutics holds roughly 61.61 Million in market capitalization claiming about 4% of equities under Health Care industry.
Spero Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Spero Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Spero Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Spero Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Spero Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -2.3 K | -2.4 K | |
| Interest Income | 3.9 M | 4.1 M | |
| Operating Income | 21.5 M | 22.6 M | |
| Net Income From Continuing Ops | 22.8 M | 23.9 M | |
| Income Before Tax | 25.4 M | 26.7 M | |
| Total Other Income Expense Net | 3.9 M | 4.1 M | |
| Net Loss | -41.8 M | -43.9 M | |
| Net Income | 22.8 M | 23.9 M | |
| Income Tax Expense | 2.6 M | 2.7 M | |
| Net Interest Income | 3.9 M | 4.1 M | |
| Non Operating Income Net Other | 749.7 K | 1.2 M | |
| Change To Netincome | 18.1 M | 19 M | |
| Net Income Per Share | 0.43 | 0.45 | |
| Income Quality | (1.45) | (1.37) | |
| Net Income Per E B T | 0.90 | 0.74 |
Spero Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Spero Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Spero Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Spero Therapeutics' important profitability drivers and their relationship over time.
Use Spero Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Spero Therapeutics Pair Trading
Spero Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Spero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spero Therapeutics to buy it.
The correlation of Spero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Spero Therapeutics position
In addition to having Spero Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Government Funds Thematic Idea Now
Government Funds
Funds or Etfs that invest in fixed income securities issued by national government to finance government spending or to facilitate Federal Reserve monetary policies. The Government Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Government Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
To fully project Spero Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Spero Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Spero Therapeutics' income statement, its balance sheet, and the statement of cash flows.